BioAlliance Pharma receives funding for novel cancer therapy
Specialty pharmaceutical company BioAlliance Pharma, focused on the treatment of opportunistic infections in cancer and AIDS has received Euro 6.4m in fundingfrom OSEO (the French state innovation agency) for the development of innovative cancer treatments.
Specialty pharmaceutical company BioAlliance Pharma, focused on the treatment of opportunistic infections in cancer and AIDS has received Euro 6.4m in fundingfrom OSEO (the French state innovation agency) for the development of innovative cancer treatments.
The company will devote the funds to the development of its novel therapeutic entities for the treatment of invasive cancers.
The funding has been awarded to the "Cancer Anti-invasive Program" (CAP) private-public consortium which comprises two innovative SMEs (Oroxcell and Xentech), two mid-sized
companies (Novasep and CIT) - all of which will make project investments - and two academic centers of excellence (the Ecole Normale Superieure de Cachan and the Institut Gustave Roussy de Cancerologie).
The collaborative program will enable the development of two therapeutic products up to the commercialisation phase: AMEPTM (a biotherapy indicated in invasive melanoma) and a first-in-class anticancer drug that targets invasive cancers and makes tumour cells revert to a normal phenotype.
In parallel, the consortium will develop innovative animal models of invasive cancers with Xentech, highly predictive genotoxicity tests with Oroxcell and immunotoxicology tools with CIT. Novasep will develop an r&d-phase pilot facility for generating highly potent active ingredients (HPAIs) .
In collaboration with BioAlliance Pharma, the academic centers of excellence will identify new markers for monitoring tumour invasion.
Dominique Costantini, BioAlliance Pharma's president and ceo, said: "This is a significant amount of public funding and constitutes a major boost for the clinical development of two of our high-added-value projects. All the consortium partners have committed to infrastructure investments and the program will provide highly innovative support for an industrial drug development pipeline".
